US Dollar: Medium-term depreciation risks build – Nordea
Nordea strategists argue that while near-term risks for the Dollar are broadly balanced, the longer-term outlook remains negative. They highlight recent weaker US data, shifting Fed expectations, low FX volatility, yield-curve steepening, rising term premium risks and stretched US asset valuations as factors likely to weigh on the Dollar and keep EUR/USD supported over time.
Balanced near term, weaker beyond
"Looking ahead, we see the near-term risks to the dollar as broadly balanced, with the potential for both appreciation and depreciation over the remainder of the year. However, we maintain our view that the dollar is likely to weaken next year."
"Should US activity data rebound and lead markets to rebuild expectations of Fed tightening, this could provide renewed support for the dollar in the near term."
"While the near-term outlook therefore looks relatively balanced, we continue to see the medium-term risks as skewed towards a weaker dollar from current levels."
"We expect the curve to steepen further over the next two years, which should ultimately weigh on the dollar."
"Taken together, we believe the combination of further US yield-curve steepening, rising fiscal and term-premium concerns and elevated US asset valuations will increasingly outweigh the support from a relatively resilient US economy."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
